ID30237A - KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES - Google Patents

KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Info

Publication number
ID30237A
ID30237A IDW00200101612A ID20011612A ID30237A ID 30237 A ID30237 A ID 30237A ID W00200101612 A IDW00200101612 A ID W00200101612A ID 20011612 A ID20011612 A ID 20011612A ID 30237 A ID30237 A ID 30237A
Authority
ID
Indonesia
Prior art keywords
insulin
fbpase
obstacles
plants
combination
Prior art date
Application number
IDW00200101612A
Other languages
English (en)
Inventor
Mark D Erion
Paul Van Poelje
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of ID30237A publication Critical patent/ID30237A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IDW00200101612A 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES ID30237A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
ID30237A true ID30237A (id) 2001-11-15

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101612A ID30237A (id) 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Country Status (25)

Country Link
EP (1) EP1143955B1 (id)
JP (1) JP2003515523A (id)
KR (3) KR100689943B1 (id)
CN (3) CN101164618A (id)
AT (1) ATE300288T1 (id)
AU (1) AU771039B2 (id)
BR (1) BR9917005A (id)
CA (1) CA2354053A1 (id)
CZ (1) CZ20012353A3 (id)
DE (1) DE69926400T2 (id)
DK (1) DK1143955T3 (id)
ES (1) ES2246586T3 (id)
HK (1) HK1046863B (id)
HU (1) HUP0402506A3 (id)
ID (1) ID30237A (id)
IL (2) IL143569A0 (id)
MX (1) MXPA01006511A (id)
NO (1) NO20013115L (id)
NZ (1) NZ512219A (id)
PL (1) PL352756A1 (id)
PT (1) PT1143955E (id)
RU (2) RU2227749C2 (id)
SK (1) SK9172001A3 (id)
WO (1) WO2000038666A2 (id)
ZA (1) ZA200105016B (id)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
MXPA02006156A (es) * 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL365779A1 (en) * 2000-07-06 2005-01-10 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
JP4719465B2 (ja) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー.ブイ. インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2515726C (en) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
BRPI0418082B8 (pt) 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質
US20070259928A1 (en) * 2004-12-13 2007-11-08 Taishi Yoshida Medicinal Composition for Treating Diabetes
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びage生成阻害剤
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ,インコーポレイテッド Aicaリボシドの放出および血液グルコースの低減のための化合物および方法
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
IL143569A0 (en) 2002-04-21
DK1143955T3 (da) 2005-11-14
WO2000038666A2 (en) 2000-07-06
KR100689943B1 (ko) 2007-03-08
HUP0402506A2 (hu) 2005-04-28
EP1143955A3 (en) 2002-08-28
DE69926400T2 (de) 2006-05-24
NO20013115L (no) 2001-08-24
BR9917005A (pt) 2002-04-02
ZA200105016B (en) 2002-09-19
HK1046863A1 (zh) 2003-01-30
WO2000038666A3 (en) 2001-11-29
KR20010099942A (ko) 2001-11-09
CN100352505C (zh) 2007-12-05
HK1046863B (zh) 2008-07-25
PL352756A1 (en) 2003-09-08
EP1143955B1 (en) 2005-07-27
AU2058300A (en) 2000-07-31
CN1714866A (zh) 2006-01-04
CZ20012353A3 (cs) 2001-12-12
ATE300288T1 (de) 2005-08-15
CN1350466A (zh) 2002-05-22
NZ512219A (en) 2004-12-24
KR20070046210A (ko) 2007-05-02
KR20060114724A (ko) 2006-11-07
JP2003515523A (ja) 2003-05-07
HUP0402506A3 (en) 2007-05-29
PT1143955E (pt) 2005-11-30
IL143569A (en) 2006-06-11
EP1143955A2 (en) 2001-10-17
AU771039B2 (en) 2004-03-11
RU2003132054A (ru) 2005-04-20
SK9172001A3 (en) 2002-04-04
ES2246586T3 (es) 2006-02-16
MXPA01006511A (es) 2004-03-19
NO20013115D0 (no) 2001-06-21
CA2354053A1 (en) 2000-07-06
RU2227749C2 (ru) 2004-04-27
DE69926400D1 (de) 2005-09-01
CN101164618A (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
TW200502385A (en) Modulation of forkhead box o1a expression
DE60118723D1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
ATE531688T1 (de) Verbindungen zur modulation des rage-rezeptors
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
EP1098642A4 (en) METHODS OF TREATING MODULATED CONDITIONS WITH LACTOSYLCERAMIDE
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
PL1865990T3 (pl) Sposób leczenia cukrzycy typu 2
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
AP9801416A0 (en) Method Of treating a plant disease.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
SE9702993D0 (sv) Anti-mikrobial komposition